AZN GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Astrazeneca plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General
AstraZeneca (LSE/STO/Nasdaq: AZN ) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Did you know?
Pays a 1.73% dividend yield.
Current Price
$184.74
-1.40%GoodMoat Value
$228.37
23.6% undervaluedProfile
Valuation (TTM)
Market Cap$286.51B
P/E27.58
EV—
P/B5.89
Shares Out1.55B
P/Sales4.74
Revenue$60.44B
EV/EBITDA15.28
Astrazeneca plc (AZN) Quality Analysis
AZN Profitability
Profitability trend analysis coming soon
AZN Growth
Growth trend analysis coming soon
AZN Financial Health
Financial health indicators coming soon
AZN Quality & Fundamental Analysis
Astrazeneca plc (AZN) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ. This quality analysis page evaluates Astrazeneca plc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Astrazeneca plc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 17.19% and a return on equity (ROE) of 21.35%. Return on assets (ROA) stands at 9.11%.
The debt-to-equity ratio is 0.61, with a current ratio of 0.94. Operating margin is 23.40%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Astrazeneca plc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.